

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
15 May 2025 (15.05.2025)



(10) International Publication Number
WO 2025/099632 A1

- (51) **International Patent Classification:**
C07K 16/24 (2006.01) *C07K 16/28* (2006.01)
- (21) **International Application Number:**
PCT/IB2024/061045
- (22) **International Filing Date:**
07 November 2024 (07.11.2024)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
23306925.1 08 November 2023 (08.11.2023) EP
- (71) **Applicant: SANOFI** [FR/FR]; 46 Avenue de la Grande Armée, 75017 Paris (FR).
- (72) **Inventors: LI, Xiangming;** c/o Sanofi, Patent Department, 450 Water Street, Cambridge, Massachusetts 02141 (US). **MUKAI, Kaori;** c/o Sanofi, Patent Department, 450 Water Street, Cambridge, Massachusetts 02141 (US). **PARK, Sunghae;** c/o Sanofi, Patent Department, 450 Water Street, Cambridge, Massachusetts 02141 (US). **SUN, Victor Zhao;** c/o Sanofi, Patent Department, 450 Water Street, Cambridge, Massachusetts 02141 (US). **ZHOU, Qun;** c/o Sanofi, Patent Department, 450 Water Street, Cambridge, Massachusetts 02141 (US).

- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) **Title:** CD25 BASED LYSOSOMAL DEGRADER AND USES THEREOF

(57) **Abstract:** The present disclosure provides a method comprising: contacting a CD25 positive cell with either a multispecific or a monospecific CD25 binding protein. The multispecific binding protein can comprise: a) a first cell surface binding moiety that specifically binds to CD25 on the surface of the CD25 positive cell, wherein the first cell surface binding moiety comprises at least one immunoglobulin domain or an antigen binding fragment thereof; and b) a second binding moiety that is operatively linked to the first cell surface binding moiety and that specifically binds to the target protein, wherein specific binding of the multispecific binding protein to the CD25 facilitates the internalization of the target protein into the CD25 positive cell. The internalization results in lysosomal degradation of the target protein. A monospecific CD25 binding protein can comprise at least one ISVD that specifically binds to a CD25 (CD25 ISVD) on the surface of a CD25 positive cell and can be utilized in a multispecific CD25 binding protein. The binding of the monospecific CD25 binding protein can modulate cell regulation, e.g., resulting in inactivation of T cells. The present disclosure also provides multispecific and monospecific binding protein compositions, host cells for making the multispecific and monospecific binding protein compositions, and methods of using the multispecific and monospecific binding protein compositions to treat disease.

WO 2025/099632 A1